$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
不止肝癌肾癌,索拉菲尼也可用于治疗甲状腺癌!
2025-10-19 11:44:20
Check Details
乐伐替尼治疗甲状腺癌延长无进展生存期
2025-10-19 11:44:20
Check Details
分化型甲状腺癌靶向药物——多吉美
2025-10-19 11:44:20
Check Details
索拉非尼治疗甲状腺癌疗效优于安慰剂
2025-10-19 11:44:20
Check Details
国内首个甲状腺癌靶向药——多吉美
2025-10-19 11:44:20
Check Details
临床中多吉美可以治疗哪些癌症?
2025-10-19 11:44:20
Check Details
仑伐替尼治疗分化型甲状腺癌
2025-10-19 11:44:20
Check Details
多吉美——甲状腺癌患者的福音
2025-10-19 11:44:20
Check Details
多吉美是最早用于治疗甲状腺癌的靶向药
2025-10-19 11:44:20
Check Details
多吉美可以用于治疗分化型甲状腺癌
2025-10-19 11:44:20
Check Details
甲状腺癌患者的希望——多吉美
2025-10-19 11:44:20
Check Details
乐伐替尼治疗甲状腺癌的临床试验
2025-10-19 11:44:20
Check Details
1
2
...
2444
2445
2446
2447
2448
2449
2450
...
4159
4160
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Cemiplimab: A PD-1 Checkpoint Inhibitor for Skin Cancers and Non-Small Cell Lung Cancer
2
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
3
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
4
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
5
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
6
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
7
Vemurafenib: Mechanism of Action and Clinical Role in BRAF V600E–Targeted Therapy
8
Sotorasib (Lumakras): A Comprehensive Guide to the First KRAS G12C-Targeted Inhibitor
9
Comprehensive Interpretation of Osimertinib: Efficacy, Side Effects and Medication Standards
10
Sotorasib: Can the First KRAS G12C-Targeted Therapy Cure Cancer?
11
Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained
12
Belzutifan (Welireg): HIF-2α Inhibitor for VHL-Associated Tumors and Renal Cell Carcinoma — Dosing Phases, Survival Data, and Efficacy Insights